PVI
IOVA icon

Pura Vida Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Pura Vida Investments’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-144,528
Closed -$1.39M – 216
2022
Q3 		$1.39M Buy
+144,528
New +$1.67M 0.08% 150

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pura Vida Investments's IOVA Position: Q4 2022 in Review

Pura Vida Investments sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 144,528 shares — an estimated $1.39M sold.

Pura Vida Investments first reported a position in IOVA in Q3 2022 and held it in 1 quarter. The position peaked at $1.39M in Q3 2022. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

  • Pura Vida Investments reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Pura Vida Investments sold 144,528 Iovance Biotherapeutics shares in Q4 2022, an estimated $1.39M.
  • Pura Vida Investments first reported a position in Iovance Biotherapeutics in Q3 2022 and held it in 1 quarter.
  • Pura Vida Investments's Iovance Biotherapeutics position peaked at $1.39M in Q3 2022.
  • 218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.